
Pulmonx (LUNG) Stock Forecast & Price Target
Pulmonx (LUNG) Analyst Ratings
Bulls say
Pulmonx is expected to see a return to growth in both its US and international markets in the back half of 2026, with double-digit growth exiting the year. The company has implemented cost restructuring initiatives resulting in improved gross margins and decreased operating expenses, and the completion of enrollment in the AeriSeal Convert II trial in 2027 may provide further growth potential in the future. However, risks such as clinical/regulatory, financial, and market share remain.
Bears say
Pulmonx is facing a challenging outlook due to disruptions in the U.S. market and delays in registration renewal in China, leading to a decline in revenue and weak financial performance in the first quarter. Despite management's reassurance and refinancing activities strengthening the balance sheet, a cautious approach towards revenue guidance for the coming years shows a lack of confidence in near-term growth potential. Risks such as clinical and regulatory, partnership and financial, and commercial risks, as well as challenges in maintaining market share, present significant hurdles for the company's long-term success.
This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.
Pulmonx (LUNG) Analyst Forecast & Price Prediction
Start investing in Pulmonx (LUNG)
Order type
Buy in
Order amount
Est. shares
0 shares